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Abstract
We reported that squalamine is a membrane-active molecule that targets the membrane integrity as demonstrated by the
ATP release and dye entry. In this context, its activity may depend on the membrane lipid composition. This molecule shows
a preserved activity against bacterial pathogens presenting a noticeable multi-resistance phenotype against antibiotics such
as polymyxin B. In this context and because of its structure, action and its relative insensitivity to efflux resistance
mechanisms, we have demonstrated that squalamine appears as an alternate way to combat MDR pathogens and by pass
the gap regarding the failure of new active antibacterial molecules.
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Introduction
The emergence of multidrug resistant bacteria/pathogens has
highlighted the need for the development of new antibiotics.[1–3]
In this area, drug resistance of Gram-positive organisms has
received significant attention with respect to Gram-negative
bacteria which are innately resistant to many common antibiotics
due to their envelope structure. In Gram-positive and Gram-
negative bacteria, resistance to membrane active antibiotics
requires major changes in membrane organization, which in turn
influence the permeability barrier increasing susceptibility to
hydrophobic antibiotics. The outer membrane of Gram-negative
bacteria forms an effective barrier to such molecules.[4]
Consequently, numerous antibiotics that are active against
Gram-positive organisms are much less active against Gram-
negative bacteria. In the latter case, the outer membrane contains
lipopolysaccharide (LPS) which creates the asymmetry of the
membrane architecture (Figure 1).[5–7] It is widely held[8] that
the permeability barrier of the outer membrane is increased via
cross-bridging between LPS and divalent cations.[9,10] Thus,
metal ion chelators such as EDTA, certain cationic antimicrobial
peptides[11–13] and polyamines[14–16], which can alter the
binding of divalent cations, are able to disrupt the organization of
the outer membrane, increasing its permeability, and therefore
sensitise bacteria to hydrophobic antibiotics. In this context, an
attractive approach for the development of antibacterial agents is
the use of compounds targeting outer membranes of Gram-
negative bacteria since they are not expected to readily induce
resistance formation. In recent years, a wide variety of low
molecular weight antibiotics including peptides, lipids and
alkaloids have been isolated from diverse animal spe-
cies.[11,12,17–19] Among these substances, a water soluble
cationic amino sterol namely squalamine 1 (7,24-dihydroxylated-
24 sulfated cholestane conjugated to spermidine group at C-3) has
been isolated from the dogfish shark Squalus acanthias (Figure 2).
This compound exhibits potent antimicrobial activity and high
minimum haemolytic concentration (.200 mg/mL) suggesting its
potential application in human medicine.[20–24] We will report
on the the broad spectrum of antibacterial activity of squalamine
against sensitive and resistant bacterial strains. We also demon-
strate its mechanism of action towards Gram-negative bacteria
suggesting that this molecule constitutes one of the most
appropriate responses against the questionable emergence of
multidrug resistant Gram-negative bacteria and associated noso-
comial diseases.
Results and Discussion
Our first study concerning the antimicrobial activities of
squalamine 1 demonstrated its efficiency towards fungal and
bacterial strains with Minimum Inhibitory Concentrations (MIC)
varying from 2.5 to 25 mg/mL (Table 1–2). It is also noteworthy
that similar activities have been demonstrated against sensitive and
resistant Gram-negative bacteria (Escherichia coli and Pseudomonas
aeruginosa). The re-use of ‘‘old’’ drugs such as polymyxins has been
proposed as an alternative or rescue therapy for patient infected by
MDR strains.[25,26] We have recently reported that two clinical
Enterobacter aerogenes isolates have developed resistance to polymyx-
ins involving an alteration of LPS after colistin was used during the
therapy. This modification did not alter the protein profile of outer
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2765membrane.[27] The first isolate, strain C (Table 3) presenting a
polymyxin B susceptibility was sensitive to low concentrations of
squalamine 1. Interestingly, clinical isolates D and E that
presented a high level of polymyxin resistance (32-fold increase
of MIC) exhibited a decrease of squalamine susceptibility with a
five-fold increase of the corresponding MIC. This result suggested
that the alterations of LPS previously reported in these isolates and
causing the resistance towards polymyxin B[27], are able to
modulate the squalamine activity. In this context, regarding the
other antibiotic families, squalamine offers advantages associated
with its activity properties. The squalamine action is preserved
even in MDR clinical isolates that overexpress various mecha-
nisms of resistance including drug efflux pumps, alteration of
membrane permeability caused by absence of porins, enzymatic
barrier, all well-known mechanisms which induce high level of
resistance towards quinolones, ß-lactams, phenicols, etc (Table 1–
3). For instance: (i) strain 289 was completely devoid of porins,
expressed high level of AcrAB-Tol C efflux and a simultaneous
overproduction of b-lactamase activity, (ii) strain 298 (289
derivative) exhibited the same phenotype but was deleted of Tol
C efflux component, (iii) strain C was porin defficient, overex-
pressed AcrAB-Tol C efflux and exhibited a lipopolysaccharide
(LPS) wild type profile, (iv) strains D and E had same phenotype
plus LPS modifications.[27,28] Thus, the activity of squalamine 1
suggests in a first approach that its biological activity results from
the synergistic combination of an anionic bile salt with spermidine,
each of which independently exhibit considerably less antibiotic
activity than squalamine 1.[29,30]
Even if strong antibacterial activities have been noticed, the
mechanism of action of squalamine towards Gram-negative
bacteria remains questionable. Thus, two possible modes of action
for such an antibacterial molecule can be underlined (i)
competitive binding to a cell-surface exposed receptor (e.g. such
as porin)[6,10] involved in key cellular processes and (ii) channel or
pore formation in the cytoplasmic membrane. Recently, Katsu et
al. examined the structure-activity relationship between original
polyamines (naphthylacetylspermine and methoctramine) and the
outer membrane of Gram-negative bacteria demonstrating that
lipophilic moieties and a number of amino groups in polyamines
were important to permeabilisation.[31]
A bioluminescence method was used to determine the effect of
squalamine addition on the intracellular pool of bacterial ATP.
The detection of external concentration of ATP was then used as a
reporter reflecting the permeabilizing effect of squalamine along
with the dose-effect relationships. Thus, it clearly appears that for
a squalamine concentration of about 20 mg/mL, 80% of the
intracellular ATP has been released in the medium suggesting the
disruption of the membrane barrier (Figure 3). In addition to ATP
release measurements, effect of squalamine on bacterial mem-
brane integrity was also assessed using the cell-impermeable
DNA/RNA dye propidium iodide (PI) (Figure 4). Results showed
Figure 1. Gram negative bacteria envelope.
doi:10.1371/journal.pone.0002765.g001
Figure 2. Structure of squalamine 1.
doi:10.1371/journal.pone.0002765.g002
Table 1. Antimicrobial activities of squalamine 1.
Sensitive
Strain MIC, mg/mL
S. cerevisiae
(CIP 28383)
C. albicans
(CIP 1180-79)
S. aureus
(CIP 4.83)
E. faecalis
(CIP 103015)
E. hirae
(ATCC 10541)
E. coli
(ATCC 54127)
P. aeruginosa
(ATCC 15442)
E. aerogenes
(ATCC 15038)
Squalamine 25 .20 3.12 12.5 10 2.5 8 20
doi:10.1371/journal.pone.0002765.t001
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fluorescence. At a 1.25 mg/mL concentration, squalamine did not
significantly affect PI-associated fluorescence (263.5-fold increase,
p=0.42). Increase only started to be significant at 2.5 mg/mL
(8.063.4 fold increase (p,0.05)) and was maximal at 25 mg/mL
squalamine concentration (110.0612.5-fold (p,0.001)). Similarly,
CTAB known to cause bacterial permeabilisation, induced
equivalent increases in PI-associated fluorescence 100.0611.5-
fold increase compared to vehicle-treated bacteria, p,0.001).
Finally, in order to investigate membrane alterations associated
with squalamine action, we have used an assay based on
fluorescent microscopy (Live/Dead BacLight, Molecular Probes)
(Figure 5). In that assay, live bacteria appear green whereas dead
bacteria with an alteration of their membrane permeability are
red. At 0 or 1.25 mg/mL of squalamine, all bacteria appeared
green (Figure 5 A and B). Red/dead bacteria started to be
observed with concentration of squalamine higher than 2.5 mg/
mL (Figure 5, C). Moreover, the cytotoxicity increased when
bacteria colonies are treated with a higher squalamine concentra-
tion (i.e. 100 mg/mL), under this condition, all the bacteria were
stained red (Figure 5, F) in contrast to the untreated ones
fluorescing green.
On the other hand, it is well known that the effects of chaotropic
agents can be impaired by exogenous divalent cationic ions (Mg
2+
or Ca
2+).[5] In this context, the effect of various monovalent or
divalent ions on bactericidal activity of squalamine 1 has been
investigated using 1 mM concentration salts. As shown in Table 4
the addition of monovalent salts did not block the activity of
squalamine towards E. coli whereas this later was completely
abolished by the same concentration of divalent ions such as
MgCl2 or CaCl2. Regarding these divalent salts, it was
demonstrated that the full activity of squalamine is obtained at
low concentrations i.e. approximately 0.09 mM.
Table 2. Antimicrobial activities of squalamine 1 towards
bacteria resistant strains.
Bacteria resistant strains MIC (mg/mL)
E. coli AG100 2
E. coli AG100A 1
E. coli AG100Atet 2
P. aeruginosa PA01 16
P. aeruginosa Z61 4
P. aeruginosa 124 16
doi:10.1371/journal.pone.0002765.t002
Table 3. Antibacterial susceptibility of various Multidrug resistant (MDR) E. aerogenes clinical isolates expressing various antibiotic
resistance mechanisms.
E. aerogenes strains MIC (mg/mL)
Norfloxacin Chloramphecol Cefepime Polymyxin B Squalamine
289, MDR isolate 256 512 64 nd 4
298, 289 tolC- derivative 16 32 64 nd 2
C, MDR isolate 256 16 32 0.25 2.5
D, MDR isolate 128 16 8 16 10
E, MDR isolate 128 16 8 32 12.5
doi:10.1371/journal.pone.0002765.t003
Figure 3. Measurement of squalamine concentration effect on E. coli ATP efflux.
doi:10.1371/journal.pone.0002765.g003
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tion of the E. coli ATP efflux squalamine-dependent was observed
in the presence of divalent ions at various concentrations after
10 minutes of incubation (Figure 6). Thus, NaCl and NaH2PO4
did not lead to any inhibition on E. coli ATP efflux in the presence
of squalamine whereas a dramatic inhibition of this efflux was
observed in the presence of CaCl2 or MgCl2. Moreover, a total
inhibition of the ATP efflux was reached by a concentration of
about 5 mM or 2.5 mM for MgCl2 or CaCl2, respectively.
Many groups have observed the antibacterial effect of cationic
surfaces on Gram-positive as well as Gram-negative bacteria. This
suggests that the mechanism is not system-specific, contrary to that
which is generally the case with antibiotics. We surmise, as already
hinted by others[32], that the death process involves electrostatic
interactions and is related to the high density of charges exposed at
the surface of bacterial membranes. The architecture of LPS, the
main component of outer leaflet of the outer membrane, favors the
presence of a large number of negative charges that may stimulate
the interactions with cationic substrates.[6,33] The role of LPS is
partially suggested with the modulation of squalamine activity in
polymyxin resistant isolates and (Table 3).
To propose the existence of a charge-density threshold in the
squalamine mode of action, we are helped by recent advances in
the understanding of the electrostatic interactions between
polyelectrolyte chains and oppositely charged surfaces.[32] It has
been gradually realized that adsorption in such cases is driven by
the release in solution of the counterions initially confined within
the respective electrical double layers. The same process applies to
bacteria, which can be crudely considered as large two
dimensional polyelectrolytes. Upon adsorption on a cationic solid
substrate, the electrostatic compensation of the negative charges of
the bacterial envelope is provided by the cationic charges of the
substrate, and the bacteria lose their natural counterions.
As previously outlined, squalamine is an amphipathic com-
pound which interacts with various membrane glycerophospholi-
pids with distinct affinities.[34] As phosphatidylglycerol is the main
glycerophospholipid in bacterial membranes whereas phosphati-
dylcholine is more abundant in eukaryotic membranes, this may
explain why squalamine could kill bacteria more easily than
mammalian cells. Nevertheless, although Gram-positive bacteria
have a single membrane that is enriched in phosphatidylglycerol,
Gram-negative bacteria also have an external membrane in which
the predominant lipid is lipopolysaccharide (LPS). LPS is the
major glycolipid recovered from a Folch extract of Gram-negative
E. coli bacteria. To study the potential interaction with squalamine
and a reconstituted bacterial membrane containing LPS, a lipid
extract of E. coli enriched in LPS was spread at the air-water
interface where it formed a stable lipid monolayer. Squalamine
was then added in the aqueous subphase and its insertion within
the LPS film was assessed by surface pressure measurements[35]
As shown in Table 5, squalamine penetrated the LPS monolayer
at concentrations as low as 0.5 mg/mL. In contrast, higher doses of
squalamine were necessary to allow its insertion in monolayers
consisting of either neutral glycosphingolipids or gangliosides
extracted from lymphocytes. Thus, as far as glycolipids are
concerned in early squalamine-membrane interactions, it is clear
that bacterial LPS is significantly more active than eucaryotic
glycolipids. Squalamine also interacted with matured lipid A (the
membrane-anchored backbone of LPS), in a divalent cation-
dependent way. Indeed, this squalamine-membrane interaction is
highly cationic divalent ion dependent which is consistent with the
previously demonstrated lack of activity of squalamine in the
presence of such ions in the medium. Moreover, squalamine
interacted very poorly with GalCer, but very actively with
ceramide (Cer), the membrane-anchored backbone of sphingolip-
ids. This may suggest that the insertion of squalamine into
eukaryotic membranes could be impaired by the sugar part of
glycolipids. Overall these data provide a biochemical basis for the
potent activity of squalamine on bacterial Gram-negative and
Gram-positive membranes and its relative lack of activity on
eukaryotic membranes. Further physicochemical studies will be
conducted in the near future in order to decipher the molecular
mechanisms (including divalent cation dependence) controlling
this striking lipid selectivity.
Figure 4. Effect of squalamine on bacterial membrane integrity assessed by fluorescence measurement of propidium iodide – DNA/
RNA interactions. Results are expressed in relative fluorescence unit (RFU) as Mean6S.D. (n=3, three independent experiments).
doi:10.1371/journal.pone.0002765.g004
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Squalamine is a membrane-active molecule that targets the
membrane integrity as demonstrated by the ATP release and dye
entry. Consequently, its activity may depend on the membrane
lipid composition. It is worthwhile mentioning that the alteration
of LPS involved in the polymyxin-resistant clinical isolates
moderately changes the squalamine MIC preserving the activity
spectrum of the molecule compared to polymyxin B. Thus, if we
consider that squalamine acts as a ‘‘membranotropic’’ molecule, it
remains possible to observe less susceptible strains like those
isolated after polymyxin treatment. However, the resistant variants
must preserve a sensitivity level since the adaptation stress requires
strong changes in membrane structure which drastically deal with
intrinsic membrane stability and the bacterial fitness. In addition,
this molecule shows a preserved activity against bacterial
pathogens presenting a noticeable MDR phenotype concerning
usual antibiotics. Squalamine has membranotropic properties
regarding its bacterial membrane activity and due to its structure
containing a cholestanol core it exhibits a moderate level of side
effect on eukaryotic cells at doses that kill MDR bacterial
pathogens. In this context and because of its structure, action
and its relative insensitivity to efflux resistance mechanisms,
squalamine may be an alternate way to combat MDR pathogens
and by pass the gap regarding the failure of new active
antibacterial molecules. This aspect is especially important since
some recently described molecules having an active antibacterial
spectrum are also substrates for efflux pump systems resulting in a
decrease of activity in MDR strains, e.g. peptide deformylase
inhibitor, plectasin, platensimycin.[36–38]
Materials and Methods
Determination of minimal inhibitory concentrations
Antimicrobial activity of the compounds was studied by
determination of minimal inhibitory concentrations (MIC) ac-
Figure 5. Fluorescence-based microscopic evaluation of the effect of squalamine on bacterial integrity and survival. E. Coli cultures
(10
9/mL) were either left untreated (A) or treated with increasing squalamine concentrations: 1.25 mg/mL (B), 2.5 mg/mL (C), 5 mg/mL (D), 10 mg/mL
(E), 100 mg/ml (F). Suspensions of cultured E. Coli were then stained with the Live/Dead BacLight bacterial Viability kit, as described in material and
methods. Scale bar (10 mm).
doi:10.1371/journal.pone.0002765.g005
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dilution methods. All the reference strains were issued from the
Institut Pasteur collection (Paris). The other reference strains and
clinical isolates were from the UMR-MD1 collection and have
been previously described.[27,28,39] The bacteria strains were
grown on trypticase soy agar (Becton Dickinson) at 37uCi nL Bo r
MH broth for E. coli, E. aerogenes and S. aureus or BHI broth for E.
faecalis. Inocula were prepared in the respective medium by
ajusting the cell density.
Antimicrobial activities of the compounds were determined by
using a broth microdilution method performed in sterile 96-well
microplates. The molecules were diluted in water and were
transferred to each microplate well in order to obtain a two-fold
serial dilution and inocullum containing 2–6 10
5 CFU of each
bacteria was added to each well. A number of wells were used for
positive controls, inoculum viability and solvent effect. Results
were read after 18 hours at 37uC and the MIC was the lowest
concentration of the antibacterial agent at which no growth was
detected. MIC values are the mean of three independent
experiments.
Measurement of ATP efflux
Squalamine solutions were prepared in doubly distilled water at
different concentrations. A suspension of growing E.coli to be
studied in LB broth was prepared and incubated at 37uC. 90 mLo f
this suspension was added to 10 mL of squalamine solution and
vortexed for 1 second. 50 mL of luciferin-luciferase reagent (Yelen,
France) was immediately added to the precedent mix and
luminescent signal quantified with a Lucy luminometer (Yelen,
France) for five seconds. ATP concentration was quantified by
internal sample addition.
Measurement of ATP efflux inhibition in E. coli in the
presence of squalamine (25 mg/mL) and various mono
and divalent salt solutions
1 M salts (CaCl2, MgCl2, NaH2PO4, NaCl) solutions were
prepared in doubly distilled water and diluted in a 250 mg/mL
squalamine solution for 10 minutes at room temperature. Then,
ATP efflux was measured with the protocol described above.
Results were expressed as ATP efflux percent inhibition relative to
the salt free squalamine solution.
Membrane permeability assessment
Over night bacterial suspensions of E. coli in LB were
centrifuged 10 min at 10 000 g. Bacterial pellets were resuspended
in PBS at 2.5610
9 bacteria per mL, as bacterial permeabilisation
assays giving identical results in PBS or LB. Bacteria were added
into 96-well black NUNC plate with 0.5610
9 bacteria added per
well. The cell-impermeable DNA/RNA dye propidium iodide (PI,
Sigma) was then added to bacteria at a final concentration of
30 mM. After 10 min of equilibration at 37uC, bacteria were
treated with dye alone or with increasing concentrations of
squalamine; CTAB at 58 mg/mL (i.e. 160 mM)[40] being used as
positive control of membrane permeabilisation. Finally, fluores-
cence was measured after 30 min of incubation at 37uC using a
microplate Fluoroscan Ascent spectrofluorometer (excitation at
Table 4. Effects of various monovalent or divalent salt
solutions (1 mM) on bactericidal activity of squalamine
(2.5 mg/mL).
Salts [1 mM] Inhibition effect
a
No salt NI
NaCl NI
NaBr NI
NaI NI
KCl NI
KBr NI
CaCl2 ++
MgBr2 ++
MgCl2 ++
aNI: No inhibition; ++: Total inhibition (100% Bacterial survival).
doi:10.1371/journal.pone.0002765.t004
Figure 6. ATP efflux inhibition in E. coli in the presence of squalamine (5 mg/mL) and various mono and divalent salt solutions.
doi:10.1371/journal.pone.0002765.g006
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have shown that maximal fluorescence was obtained at that time
independently of the dose of squalamine.
Fluorescence microscopy
In order to investigate membrane damage, we have used the
fluorescence based Live/Dead BacLight assay (Molecular Probes).
This assay contains a mixture of two nucleic acid stains: a green-
fluorescent Stylo 9 stain and a red-fluorescent propidium iodide
stain. These stains differ to their ability to penetrate healthy
bacterial cells. Intact cell membranes stains green, whereas
bacteria with damaged membranes stains red. Live and dead
bacteria were viewed simultaneously by fluorescence microscopy
with suitable optical filter sets. Escherichia coli cells (10
9 CFU/mL)
were incubated in the presence of different concentrations of
squalamine (1.25 mg/mL, 2.5 mg/mL, 5.0 mg/mL, 10 mg/mL,
100 mg/mL) for 30 minutes at 37uC. Suspensions of treated and
untreated cells were stained according to BacLight assay
instruction and 5 mL of each bacterial suspensions were subse-
quently deposited on slides and analyzed using a fluorescence
microscope.
Measurements of squalamine interactions with various
bacterial and eucaryotic lipids
The lipids were spread at the air-water interface at an initial
surface pressure of 15 mN.m
21. After evaporation of the solvent
(hexane/chloroform/ethanol; 11:5:4, vol:vol:vol), squalamine was
injected in the pure aqueous subphase (volume 800 mL). The
variations of the surface pressure were continuously recorded with
a fully automated microtensiometer (mTROUGH SX, Kibron Inc.
Helsinki, Finland). All experiments were carried out in a controlled
atmosphere at 20uC61uC. The data were analyzed with the
Filmware 2.5 program (Kibron Inc. Helsinki, Finland). The
accuracy of the system under our experimental conditions was
60.25 mN.m
21 for surface pressure. A plus means that the
surface pressure increase was above 5 mN.m
21 after 60 minutes of
interaction, a minus means that during the same period of time,
the surface pressure increase did not exceed 2 mN.m
21. Bacterial
and eukaryotic lipids were extracted and submitted to a Folch
partition as described previously.[41] Lipopolysaccharide (LPS)
was the only glycolipid recovered from the Folch lower phase of
the bacterial extract, as demonstrated by high performance thin
layer chromatography. The Folch lower phase of lymphocyte
lipids contained GlcCer, LacCer, Gb3 and Gb4. The upper phase
contained GM1, GM3 and GD3. Pure Lipid A, Cer, GalCer,
GM1, GD3 and GT1b were purchased from Sigma. Each
experiment was performed three times with similar results.
Acknowledgments
We acknowledge Pr M. Zasloff from Georgetown University, Washington
(USA) providing us a sample of squalamine. Thanks to L. Amaral and S.
Fanning for their helpful advices. We thank Emilie Donatin and Jacqueline
Chevalier for help during determination of bacteriological activities.
Author Contributions
Conceived and designed the experiments: JF MM JMP JMB. Performed
the experiments: CS CL NV JF MM NT JMP JMB. Analyzed the data:
JMB. Contributed reagents/materials/analysis tools: CS CL. Wrote the
paper: NV YL JF MM JMP JMB.
References
1. Armstrong D, Neu H, Peterson LR, Tomasz A (1995) The prospects of
treatment failure in the chemotherapy of infectious diseases in the 1990s. Microb
Drug Resist 1: 1–4.
2. Bax R, Bywater R, Cornaglia G, Goossens H, Hunter P, et al. (2001)
Surveillance of antimicrobial resistance-xhat, how and whither? Clin Microbiol
Infect 7: 316–325.
3. Tomasz A (1994) Multiple-antibiotic-resistant pathogenic bacteria. A report on
the Rockefeller University workshop. N Engl J Med 330: 1247–
1251.
4. Labischinski H, Barnickel G, Bradaczek H, Naumann D, T. RE, et al. (1985)
High state of order of isolated bacterial lipopolysaccharide and its possible
contribution to the permeation barrier property of the outer membrane.
J Bacteriol 162: 9–20.
5. Vaara M (1992) Agents that increase the permeability of the outer membrane.
Microbiol Rev 56: 395–411.
6. Nikaido H (1996) Outer membrane. In: Neidhardt FC, Curtis III R,
Ingraham JL, eds. Escherichia coli and Salmonella: cellular and molecular
biology. washington: ASM press. pp 29–47.
7. Hancock R (1997) The bacterial outer membrane as a drug barrier. Trends
Microbiol 5: 37–42.
8. Murata T, Tseng W, Guina T, Miller SI, Nikaido H (2007) PhoPQ-mediated
regulation produces a more robust permeability barrier in the outer membrane
of Salmonella enterica serovar typhimurium. J Bacteriol 189: 7213–7222.
9. Vaara M (1993) Outer membrane permeability barrier to azithromycin,
clarithromycin, and roxithromycin in gram-negative enteric bacteria. Anti-
microb Agents and Chemother 37: 354–356.
10. Nikaido H (2003) Molecular basis of bacterial outer membrane permeability
revisited. Microbiology and Molecular Biology Reviews 67: 593–656.
11. Zasloff M (1992) Antibiotic peptides as mediators of innate immunity. Curr
Opin Immunol 4: 3–7.
12. Zasloff M (1994) Antibacterial molecules from frogs, sharks and man. Phylogenet
Perspect Immun Insect Host Def. pp 31–41.
13. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature
(London, United Kingdom) 415: 389–395.
14. Burns MR, Wood SJ, Miller KA, Nguyen T, Cromer JR, et al. (2005) Lysine-
spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccha-
ride sequestrants. Bioorg Med Chem 13: 2523–2536.
15. Hayrinen J, Haseley S, Talaga P, Muhlenhoff M, Finne J, et al. (2002) High
affinity binding of long-chain polysialic acid to antibody, and modulation by
divalent cations and polyamines. Molecul Immunol 39: 399–411.
Table 5. Measurements of squalamine interactions with various bacterial and eukaryotic lipids.
Squalamine
concentration
(mg/mL)
E. coli Extract
(LPS)
Lymphocyte
Neutral GSL
Lymphocyte
Gangliosides Lipid A
Lipid A 1 mM
MgCl2 GalCer Cer GM1 GD3 GT1b
0.5 + 22 2 2 2 + 222
1.0 + 22 2 2 2 + 222
1.5 ++ 2 + 22 + 2 + 2
2.0 ++ 2 + 22 ++ + 2
$2.5 ++ + + ++ + + + +
doi:10.1371/journal.pone.0002765.t005
The Antibiotic of the Future
PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e276516. Sol V, Branland P, Chaleix V, Granet R, Guilloton M, et al. (2004) Amino
porphyrins as photoinhibitors of Gram-positive and -negative bacteria. Bioorg
Med Chem Lett 14: 4207–4211.
17. Stone R. Deja vu guides the way to new antimicrobial steroid. Science 259:
1125.
18. Ahima Rexford S, Patel Hiralben R, Takahashi N, Qi Y, Hileman Stanley M, et
al. (2002) Appetite suppression and weight reduction by a centrally active
aminosterol. Diabetes 51: 2099–2104.
19. Boman HG (1991) Antibacterial peptides: key components needed in immunity.
Cell 65: 205–207.
20. Brunel JM, Letourneux Y (2003) Recent advances in the synthesis of spermine
and spermidine analogs of the shark aminosterol squalamine. Eur J Org Chem.
pp 3897–3907.
21. Brunel JM, Salmi C, Loncle C, Vidal N, Letourneux Y (2005) Squalamine: a
polyvalent drug of the future? Curr Cancer Drug Targets 5: 267–272.
22. Ding B, Guan Q, Walsh JP, Boswell JS, Winter TW, et al. (2002) Correlation of
the antibacterial activities of cationic peptide antibiotics and cationic steroid
antibiotics. J Med Chem 45: 663–669.
23. Moore KS, Wehrli S, Roder H, Rogers M, Forrest JN Jr, et al. (1993)
Squalamine: An aminosterol antibiotic from the shark. Proc Natl Acad Sci USA
90: 1354–1358.
24. Rao MN, Shinnar AE, Noecker LA, Chao TL, Feibush B, et al. (2000)
Aminosterols from the dogfish shark Squalus acanthias. J Nat Prod 63: 631–635.
25. Zavascki AP, Goldani LZ, Li J, Nation RL (2007) Polymyxin B for the treatment
of multidrug-resistant pathogens: a critical review. J Antimicrob and Chemother
60: 1206–1215.
26. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, et al. (2006) Colistin:
the re-emerging antibiotic for multidrug-resistant gram-negative bacterial
infections. Lancet Infect Diseases 6: 589–601.
27. Thiolas A, Bollet C, La Scola B, Raoult D, Pages J-M (2005) Successive
emergence of Enterobacter aerogenes strains resistant to imipenem and colistin
in a patient. Antimicrob Agents and Chemother 49: 1354–1358.
28. Pradel E, Pages J-M (2002) The AcrAB-TolC efflux pump contributes to
multidrug resistance in the nosocomial pathogen Enterobacter aerogenes.
Antimicrob Agents and Chemother 46: 2640–2643.
29. Kwon DH, Lu CD (2006) Polyamines increase antibiotic susceptibility in
Pseudomonas aeruginosa. Antimicrob Agents and Chemother 50: 1623–1627.
30. Kwon DH, Lu CD (2007) Polyamine effects on antibiotic susceptibility in
bacteria. Antimicrob Agents and Chemother 51: 2070–2077.
31. Yasuda K, Ohmizo C, Katsu T (2004) Mode of action of novel polyamines
increasing the permeability of bacterial outer membrane. Int J Antimicrob
Agents 24: 67–71.
32. Ku ¨gler R, Bouloussa O, Rondelez F (2005) Evidence of a charge-density
threshold for optimum efficiency of biocidal cationic surfaces. Microbiol 151:
1341–1348.
33. Peschel A (2002) How do bacteria resist human antimicrobial peptides? Trends
Microbiol 10: 179–186.
34. Selinsky BS, Zhou Z, Fojtik KG, Jones SR, Dollahon NR, et al. (1998) The
aminosterol antibiotic squalamine permeabilizes large unilamellar phospholipid
vesicles. Biochimica et Biophysica Acta 1370: 218–234.
35. Garmy N, Taieb N, Yahi N, Fantini J, Journal of Lipid Research (2005), 36–45.
(2005) Interaction of cholesterol with sphingosine: Physicochemical character-
ization and impact on intestinal absorption. J Lipid Res 46: 36–45.
36. Dean CR, Narayan S, Daigle DM, Dzink-Fox JL, Puyang X, et al. (2005) Role
of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus
influenzae to the novel peptide deformylase inhibitor LBM415. Antimicrob
Agents and Chemother 49: 3129–3135.
37. Mygind PH, Fischer RL, Schnorr KM, Hansen MT, Soenksen CP, et al. (2005)
Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic
fungus. Nature (London, United Kingdom) 437: 975–980.
38. Wang J, Soisson SM, Young K, Shoop W, Kodali S, et al. (2006) Platensimycin
is a selective FabF inhibitor with potent antibiotic properties. Nature (London,
United Kingdom) 441: 358–361.
39. Viveiros M, Dupont M, Rodrigues L, Couto I, Davin-Regli A, et al. (2007)
Antibiotic stress, genetic response and altered permeability of E. coli. PLoS One
2: No pp. given.
40. Niven GW, Mulholland F (1998) Cell membrane integrity and lysis in
Lactococcus lactis: the detection of a population of permeable cells in post-
logarithmic phase cultures. J Appl Microbiol 84: 90–96.
41. Fantini J, Cook DG, Nathanson N, Spitalnik SL, Gonzalez-Scarano F (1993)
Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus
is associated with cell surface expression of galactosylceramide, a potential
alternative gp120 receptor. Proc Natl Acad Sci USA 90: 2700–2704.
The Antibiotic of the Future
PLoS ONE | www.plosone.org 8 July 2008 | Volume 3 | Issue 7 | e2765